中国药物经济学2024，Vol.19Issue(3)：56-59,4.DOI:10.12010/j.issn.1673-5846.2024.03.010
丁苯酞联合依达拉奉右莰醇治疗缺血性脑卒中的疗效及成本
Efficacy and Cost of Butylphthalide combined with Edaravone Dexborneol in the Treatment of Ischemic Stroke
摘要
Abstract
Objective To explore the efficacy and cost of butylphthalein combined with Edaravone Dexborneol in the treatment of ischemic stroke.Methods After referring to the information system(HIS)of the Second Affiliated Hospital of Mudanjiang Medical College,all the hospitalized standard treatment information of ischemic stroke patients using sodium butylphthalide chloride injection combined with Edaravone dextrocamphorol injection concentrated solution and Edaravone dextrocamphorol injection concentrated solution from January 2021 to December 2021 were collected,and a total of 945 cases were obtained.In order to avoid misclassification,the baseline characteristics of the two groups of patients were confounding control.Propensity score matching method(1:1)was used to match the combination group and the control group.945 patients with ischemic stroke were finally determined to be butaphthalein combined with edaravone dexcamphorol plus conventional treatment,270 cases were in the combination group,and 270 cases in the control group were classified as edaravone dexcamphorol plus conventional treatment.The National Institutes of Health Stroke Scale(NIHSS)score,hypersensitive C-reactive protein(hs-CRP),clinical efficacy,cost and safety of the two groups were compared before and after treatment.Results After treatment,the NIHSS score and hs-CRP level of the two groups were decreased,and the decrease was greater in the combined group,with statistical significance(P<0.05).The efficiency of combination group was higher than that of control group,the difference was statistically significant(P<0.05).There was no significant difference in treatment effectiveness between the two groups(P>0.05).There was no significant difference in total drug cost,inspection cost,laboratory cost,treatment cost and direct medical cost between the two groups(P>0.05).No obvious adverse reactions occurred in both groups.Conclusion Compared with Edaravone dextrocamphorol alone,butylphthalein combined with Edaravone dextrocamphorol is more effective in the treatment of ischemic stroke,and can effectively improve the neurological function of patients,but the economy is similar.关键词
丁苯酞/依达拉奉右莰醇/缺血性脑卒中/成本-效果Key words
Butylphthalide/Edaravone Dexborneol/Ischemic stroke/Cost-effectiveness分类
医药卫生引用本文复制引用
黄俊荣,王彬,曲政,耿毅楠,顾彦铭,李龙,吴艳丽,魏威..丁苯酞联合依达拉奉右莰醇治疗缺血性脑卒中的疗效及成本[J].中国药物经济学,2024,19(3):56-59,4.基金项目
黑龙江省省属高等学校基本科研业务费科研项目(2018-KYYWFMY-0082) （2018-KYYWFMY-0082）
